Vmbook Online ordering

Icons

Icon Plc (ICON) is a global provider of drug development solutions and services to pharmaceutical, biotechnology, and medical device industries. The company is listed on the NASDAQ stock exchange under the ticker symbol "ICON."

In their most recent earnings report, Icon reported revenue of $2.36 billion for the full year 2021, representing an increase of 12.5% compared to the previous year. The company's net income for the year was $235.6 million, or $3.64 per diluted share, compared to $224.2 million, or $3.40 per diluted share, in 2020.

Icon has a strong track record of growth and profitability, driven by its expertise in drug development, clinical trial services, and data analytics. The company has a diverse portfolio of clients and a global footprint, with operations in over 40 countries.

Icon's growth is expected to continue in 2022, with the company guiding for revenue in the range of $2.65 billion to $2.75 billion, representing an increase of 12.3% to 16.5% compared to 2021.

Icon's stock has performed well over the past year, with shares up over 20% in the past 12 months. The company has a market capitalization of approximately $9.8 billion and a price-to-earnings ratio (P/E) of 27.1, which is slightly above the industry average.

Overall, Icon is a well-established and profitable company in the drug development industry, with a strong track record of growth, diversified revenue streams, and a global presence. Its stock has performed well, and the company is expected to continue its growth in the coming years.